Updated on 9 July 2014
It had invested 8.1 percent of its net sales in R&D and related spends amounting to Rs 770.85 crore in FY'13.
"Research is the backbone of our performance. In addition to a robust internal generics research programme, 2013-14 marked significant enhancement of our research capabilities," Lupin's Managing Director Mr Nilesh Gupta further explained.
Commenting on benefits derived as a result of the R&D, he said that FY 14 was a productive year for the pharma research group as efforts bore fruits in the form of 45 approvals in key advanced markets including 22 and one Supplemental NDA in the US, 10 in EU, 6 in Australia, 5 in Canada and 2 in Japan.
"The company also filed 19 ANDAs (of which, 4 are potentially first-to-file) with the US FDA, 4 MAAs with European regulatory authorities, 4 MAAs in Australia and 2 ANDS in Canada. The cumulative ANDA filings with the USFDA stood at 192 with 99 approvals. The company has 30 confirmed first-to-files including 15 exclusive ones," he said.